Spelling suggestions: "subject:"bestatin"" "subject:"estatin""
1 |
Studies on homocarnosinosis and on human tissue carnosinase and its inhibition by bestatin and by endogenous inhibitorsPeppers, Steven Carl January 1984 (has links)
Typescript. / Thesis (Ph. D.)--University of Hawaii at Manoa, 1984. / Bibliography: leaves 139-157. / Photocopy. / Microfilm. / xii, 157 leaves, bound ill. 29 cm
|
2 |
The transdermal delivery of arginine vasopressin with pheroid technology / Hanneri CoetzeeCoetzee, Hanneri January 2007 (has links)
The aim of this study was to investigate in vitro transdermal diffusion of a small peptide namely
arginine vasopressin (AVP) with the aid of the novel PheroidTM drug delivery system. Generally,
peptides seem unfit for transdermal permeation, but it was thought prudent to explore the
suitability of this lipid-based system after success was achieved with entrapment of
tuberculostatics, bacteria and viruses. Bestatin (a selective aminopeptidase inhibitor) was
employed to circumvent any skin-related degradation of the active. Therefore, the effect of
bestatin on the preservation of AVP during diffusion was investigated. Vertical Franz cell
diffusion studies were conducted with female abdominal skin, with AVP at a concentration of
150 pglml in the donor phase and Hepes buffer as the receptor phase over a twelve-hour
period. To prove entrapment of AVP within the lipid structures of the PheroidsTM, fluorescentlylabelled
samples were monitored by means of confocal laser scanning microscopy (CLSM),
which revealed definite entrapment. In vitro permeation profiles for AVP exhibited a biphasic
character, with the majority of permeation occurring during the first two hours. The PheroidTM
delivery system proved to be advantageous when applied as delivery medium. The inclusion of
bestatin has an enhancing effect on permeation probably due to its protection of AVP. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2007.
|
3 |
The transdermal delivery of arginine vasopressin with pheroid technology / H. CoetzeeCoetzee, Hanneri January 2007 (has links)
Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2007.
|
4 |
The transdermal delivery of arginine vasopressin with pheroid technology / Hanneri CoetzeeCoetzee, Hanneri January 2007 (has links)
The aim of this study was to investigate in vitro transdermal diffusion of a small peptide namely
arginine vasopressin (AVP) with the aid of the novel PheroidTM drug delivery system. Generally,
peptides seem unfit for transdermal permeation, but it was thought prudent to explore the
suitability of this lipid-based system after success was achieved with entrapment of
tuberculostatics, bacteria and viruses. Bestatin (a selective aminopeptidase inhibitor) was
employed to circumvent any skin-related degradation of the active. Therefore, the effect of
bestatin on the preservation of AVP during diffusion was investigated. Vertical Franz cell
diffusion studies were conducted with female abdominal skin, with AVP at a concentration of
150 pglml in the donor phase and Hepes buffer as the receptor phase over a twelve-hour
period. To prove entrapment of AVP within the lipid structures of the PheroidsTM, fluorescentlylabelled
samples were monitored by means of confocal laser scanning microscopy (CLSM),
which revealed definite entrapment. In vitro permeation profiles for AVP exhibited a biphasic
character, with the majority of permeation occurring during the first two hours. The PheroidTM
delivery system proved to be advantageous when applied as delivery medium. The inclusion of
bestatin has an enhancing effect on permeation probably due to its protection of AVP. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2007.
|
5 |
Pheroid technology for the topical delivery of depigmenting agents transforming growth factor–ß1 and tumor necrosis factor–a / Berenice CampbellCampbell, Berenice January 2010 (has links)
Pigmentation disorders occur in multiple conditions (Hakozaki et al., 2006:105). Although many
modalities of treatments are available, none are completely satisfactory (Briganti et al.,
2003:101). Two cytokines normally present in the skin, transforming growth factor–beta1
(TGF–81) and tumour necrosis factor–alpha (TNF–9), have been shown to inhibit melanin
synthesis (Martinez–Esparza, 2001:972).
The stratum corneum has been commonly accepted as the main barrier to percutaneous
absorption. Many techniques have been applied to overcome this barrier properties and to
enhance penetration with varying success (Pellet et al., 1997:92).
The objective of this study was to investigate the topical delivery of the above mentioned
peptide drugs with aid of the Pheroid drug delivery system. Pheroid technology is a
delivery system that promotes the absorption and increases the efficacy of dermatological,
biological and oral medicines in various pharmacological groups (Grobler et al., 2008:4).
Pheroid entraps drugs with high efficiency and delivers them with remarkable speed to target
sites (Grobler, 2004:4). In order to avoid degradation of these peptides, bestatin hydrochloride
(an aminopeptidase inhibitor), was used (Lkhagvaa et al., 2008:386).
Topical drug delivery was achieved by means of vertical Franz cell diffusion studies performed
over a 6 and 12 h period. ELISA (enzyme linked immunosorbent assay) detection was used to
detect cytokine concentrations. Entrapped cytokine solutions were monitored by confocal laser
scanning microscopy (CLSM). Upon removal of donor and receptor compartments, skin discs
were subjected to tape stripping in order to establish the amount of active present within the
stratum corneum and epidermis as well as the remaining dermis (Pellet et al., 1997:92).
When comparing the two studies with each other, it is evident that the diffused concentration
values obtained with PBS (phosphate buffer solution, pH 7.4) was lower than that obtained with
the Pheroid drug delivery system. Both cytokine concentrations were successfully delivered
topically as a minimum of concentrations for both actives were detected. This positive result
was confirmed as well by the amount of active detected in stratum corneum–epidermis and
epidermis–dermis solutions. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2011.
|
6 |
Pheroid technology for the topical delivery of depigmenting agents transforming growth factor–ß1 and tumor necrosis factor–a / Berenice CampbellCampbell, Berenice January 2010 (has links)
Pigmentation disorders occur in multiple conditions (Hakozaki et al., 2006:105). Although many
modalities of treatments are available, none are completely satisfactory (Briganti et al.,
2003:101). Two cytokines normally present in the skin, transforming growth factor–beta1
(TGF–81) and tumour necrosis factor–alpha (TNF–9), have been shown to inhibit melanin
synthesis (Martinez–Esparza, 2001:972).
The stratum corneum has been commonly accepted as the main barrier to percutaneous
absorption. Many techniques have been applied to overcome this barrier properties and to
enhance penetration with varying success (Pellet et al., 1997:92).
The objective of this study was to investigate the topical delivery of the above mentioned
peptide drugs with aid of the Pheroid drug delivery system. Pheroid technology is a
delivery system that promotes the absorption and increases the efficacy of dermatological,
biological and oral medicines in various pharmacological groups (Grobler et al., 2008:4).
Pheroid entraps drugs with high efficiency and delivers them with remarkable speed to target
sites (Grobler, 2004:4). In order to avoid degradation of these peptides, bestatin hydrochloride
(an aminopeptidase inhibitor), was used (Lkhagvaa et al., 2008:386).
Topical drug delivery was achieved by means of vertical Franz cell diffusion studies performed
over a 6 and 12 h period. ELISA (enzyme linked immunosorbent assay) detection was used to
detect cytokine concentrations. Entrapped cytokine solutions were monitored by confocal laser
scanning microscopy (CLSM). Upon removal of donor and receptor compartments, skin discs
were subjected to tape stripping in order to establish the amount of active present within the
stratum corneum and epidermis as well as the remaining dermis (Pellet et al., 1997:92).
When comparing the two studies with each other, it is evident that the diffused concentration
values obtained with PBS (phosphate buffer solution, pH 7.4) was lower than that obtained with
the Pheroid drug delivery system. Both cytokine concentrations were successfully delivered
topically as a minimum of concentrations for both actives were detected. This positive result
was confirmed as well by the amount of active detected in stratum corneum–epidermis and
epidermis–dermis solutions. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2011.
|
Page generated in 0.068 seconds